Roche Unveils New Alzheimer's Data and Launches Phase II Neuroinflammation Trial

Roche is presenting new data from its Alzheimer's disease portfolio at the CTAD Congress, including updated Phase Ib/IIa Brainshuttle™ AD study data for trontinemab. Concurrently, the company is initiating the TARBELA-AD Phase II clinical trial to evaluate RG6434, an investigational oral NLRP3 inhibitor, for early symptomatic Alzheimer's disease. This trial aims to target neuroinflammation, a key factor in the disease's progression, representing a new approach in Alzheimer's research.